Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 535-544
Open Access | Times Cited: 277

Showing 26-50 of 277 citing articles:

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
Laura A. Bolte, Karla A. Lee, Johannes R. Björk, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 705-705
Open Access | Times Cited: 44
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Johannes R. Björk, Laura A. Bolte, Andrew Maltez Thomas, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 785-796
Open Access | Times Cited: 44
Role of the microbiota in response to and recovery from cancer therapy
Stephen J. Blake, Yochai Wolf, Ben Boursi, et al.
Nature reviews. Immunology (2023) Vol. 24, Iss. 5, pp. 308-325
Closed Access | Times Cited: 41
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, et al.
Cell (2024) Vol. 187, Iss. 13, pp. 3373-3389.e16
Open Access | Times Cited: 38
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Ze-Hua Li, Weixi Xiong, Liang Zhu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 30
A gut microbial signature for combination immune checkpoint blockade across cancer types
Ashray Gunjur, Yan Shao, Timothy Rozday, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 797-809
Open Access | Times Cited: 29
A core microbiome signature as an indicator of health
Guojun Wu, Ting Xu, Naisi Zhao, et al.
Cell (2024) Vol. 187, Iss. 23, pp. 6550-6565.e11
Open Access | Times Cited: 28
Advances and prospects of biomarkers for immune checkpoint inhibitors
Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101621-101621
Open Access | Times Cited: 26
The gut–airway microbiome axis in health and respiratory diseases
Mustafa Özçam, Susan V. Lynch
Nature Reviews Microbiology (2024) Vol. 22, Iss. 8, pp. 492-506
Closed Access | Times Cited: 23
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
Isabella C. Glitza, Yongwoo David Seo, Christine N. Spencer, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1161-1175
Open Access | Times Cited: 18
Broadening oncological boundaries: the intratumoral microbiota
Ying‐Qi Lu, Han Qiao, Xi-Rong Tan, et al.
Trends in Microbiology (2024) Vol. 32, Iss. 8, pp. 807-822
Open Access | Times Cited: 17
Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy
Yunwei Yang, Yaping An, Yue Dong, et al.
EBioMedicine (2024) Vol. 100, pp. 104967-104967
Open Access | Times Cited: 16
Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 5
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Alessandra Cesano, Ryan C. Augustin, Luigi Barrea, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e008876-e008876
Open Access | Times Cited: 2
The gut microbiome and cancer response to immune checkpoint inhibitors
Francesca S. Gazzaniga, Dennis L. Kasper
Journal of Clinical Investigation (2025) Vol. 135, Iss. 3
Open Access | Times Cited: 2
The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency
Prabha Chandrasekaran, Máté Krausz, Yu Han, et al.
Microbiome (2025) Vol. 13, Iss. 1
Open Access | Times Cited: 2
A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma
Mattia Ballerini, Serena Galié, Punit Tyagi, et al.
Nature Biomedical Engineering (2025)
Open Access | Times Cited: 2
Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses
Puspendu Sardar, Benjamin S. Beresford-Jones, Wangmingyu Xia, et al.
Nature Microbiology (2025) Vol. 10, Iss. 3, pp. 795-807
Open Access | Times Cited: 1
The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
Azin Aghamajidi, Saman Maleki Vareki
Cancers (2022) Vol. 14, Iss. 15, pp. 3563-3563
Open Access | Times Cited: 55
Microbiome epidemiology and association studies in human health
Hannah VanEvery, Eric A. Franzosa, Long H. Nguyen, et al.
Nature Reviews Genetics (2022) Vol. 24, Iss. 2, pp. 109-124
Closed Access | Times Cited: 54
Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment
Hui Xu, Chenxi Cao, Yuqing Ren, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
The heightened importance of the microbiome in cancer immunotherapy
C Villemin, Anne Six, Bridget A. Neville, et al.
Trends in Immunology (2022) Vol. 44, Iss. 1, pp. 44-59
Open Access | Times Cited: 49
Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts
Xiaowen Huang, Muni Hu, Tiantian Sun, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 11, pp. 1930-1943.e4
Open Access | Times Cited: 37
Bodywide ecological interventions on cancer
Guido Kroemer, Jennifer L. McQuade, Miriam Mérad, et al.
Nature Medicine (2023) Vol. 29, Iss. 1, pp. 59-74
Closed Access | Times Cited: 33
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
Anna Spreafico, Alya Heirali, Daniel Vilarim Araújo, et al.
Annals of Oncology (2023) Vol. 34, Iss. 6, pp. 520-530
Open Access | Times Cited: 32

Scroll to top